drugset / Trial / NCT03695822

Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome

NCT03695822 ↗

Phase 4 Withdrawn Far Eastern Memorial Hospital
NaSingle-groupOpen-labelTreatment

Summary

We will get the impact of mirabegron on psychological distress, urethra and bladder blood flow and c reactive protein.

Timeline

Start
2018-12-24
Primary completion
2019-01-21
Completion
2019-01-31

Outcome

Outcome not reported

Stopped: “I did not pass the 2018 Ministry of Science and Technology research project subsidy, so I applied for the project to close the case.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirabegron Other / unclassified 25 mg —

Indications